Avani Kanubaddi - Enveric Biosciences Pres COO
| ENVB Stock | USD 0.34 0.01 2.86% |
Insider
Avani Kanubaddi is Pres COO of Enveric Biosciences
| Age | 51 |
| Address | 4851 Tamiami Trail N, Naples, FL, United States, 34103 |
| Phone | 239-302-1707 |
| Web | https://www.enveric.com |
Enveric Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.805) % which means that it has lost $0.805 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.061) %, meaning that it created substantial loss on money invested by shareholders. Enveric Biosciences' management efficiency ratios could be used to measure how well Enveric Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. As of November 21, 2024, Return On Tangible Assets is expected to decline to -0.0044. The current year's Return On Capital Employed is expected to grow to -7.99. At present, Enveric Biosciences' Non Currrent Assets Other are projected to decrease significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 1.1 M, whereas Total Assets are forecasted to decline to about 4.1 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MBA | Kiora Pharmaceuticals | 50 | |
| LaBella MS | ZyVersa Therapeutics | 66 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Susan Dexter | Sonnet Biotherapeutics Holdings | 69 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Robert Dudley | Transcode Therapeutics | 73 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Karen Cashmere | ZyVersa Therapeutics | 72 | |
| Jay Cross | Sonnet Biotherapeutics Holdings | 53 | |
| John Cini | Sonnet Biotherapeutics Holdings | 71 | |
| Pablo MD | ZyVersa Therapeutics | N/A | |
| Qiyong Liu | Transcode Therapeutics | 60 | |
| Dr MedSc | Phio Pharmaceuticals Corp | 68 | |
| Anna Moore | Transcode Therapeutics | 62 | |
| MD FACP | Sonnet Biotherapeutics Holdings | 66 | |
| Manuel Dafonseca | Sonnet Biotherapeutics Holdings | N/A | |
| Brian Strem | Kiora Pharmaceuticals | 44 | |
Management Performance
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.8 |
Enveric Biosciences Leadership Team
Elected by the shareholders, the Enveric Biosciences' board of directors comprises two types of representatives: Enveric Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Enveric. The board's role is to monitor Enveric Biosciences' management team and ensure that shareholders' interests are well served. Enveric Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Enveric Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Tucker, CEO Director | ||
| Ibrahim MD, Chief Officer | ||
| MBA IV, Interim Officer | ||
| Peter Facchini, Chief Officer | ||
| Avani Kanubaddi, Pres COO | ||
| Kevin CPA, Chief Officer |
Enveric Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Enveric Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.06 | ||||
| Return On Asset | -0.8 | ||||
| Current Valuation | (3.59 M) | ||||
| Shares Outstanding | 9.94 M | ||||
| Shares Owned By Insiders | 6.92 % | ||||
| Shares Owned By Institutions | 7.05 % | ||||
| Number Of Shares Shorted | 330.22 K | ||||
| Price To Book | 0.88 X | ||||
| Price To Sales | 0.08 X | ||||
| Gross Profit | 8.15 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Enveric Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Enveric Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Enveric Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Enveric Biosciences Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Enveric Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. For information on how to trade Enveric Stock refer to our How to Trade Enveric Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Enveric Biosciences. If investors know Enveric will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Enveric Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.42) | Revenue Per Share 37.678 | Quarterly Revenue Growth (0.07) | Return On Assets (0.81) | Return On Equity (2.06) |
The market value of Enveric Biosciences is measured differently than its book value, which is the value of Enveric that is recorded on the company's balance sheet. Investors also form their own opinion of Enveric Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Enveric Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Enveric Biosciences' market value can be influenced by many factors that don't directly affect Enveric Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Enveric Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Enveric Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Enveric Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.